The company's strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. By 2026 the company believes its commercial product portfolio will generate more than $1.2 billion in annual net sales and position Coherus as a new leader in immuno-oncology.
Cyborg Score Rationale
The company has demonstrated advancements with its pipeline, particularly through partial responses in heavily pretreated PD-1 refractory patients, with CHS-114 potentially converting "cold" tumors into "hot" tumors and proof of mechanism showing promising anti-tumor activity. However, the company faces significant regulatory and clinical risks, as several of its products have yet to receive approval, which could hinder future revenue generation.
Top Insights
Company offers biosimilar products including YUSIMRY (Humira biosimilar) and CIMERLI (Lucentis biosimilar) alongside novel immunotherapy candidates
CHS-114 shows proof-of-mechanism in heavily pretreated PD-1 refractory patients with evidence of Treg cell depletion and CD8+ T cell increase
Q4 2025 expected to show quarterly revenue of approximately $14.1 million, indicating early commercialization phase
Current market cap of $249.61 million reflects distressed valuation typical of clinical-stage biotech with execution risk
Named Competitors
LOQTORZI competitors - PD-1 inhibitors — Established PD-1 checkpoint inhibitors with extensive clinical data
YUSIMRY competitors - Humira biosimilars — Competing Humira biosimilar offerings in TNF-inhibitor space
UDENYCA competitors - Neulasta biosimilars — Pegfilgrastim biosimilar and competing support care agents
Recent Developments
(February 2026) Closed public offering of common stock led by healthcare-focused investors including Janus Henderson, HBM Healthcare, and Samsara BioCapital
(March 2026) Scheduled to report full year and fourth quarter 2025 financial results on March 9, 2026
(January 2026) Corporate presentation outlining strategy and pipeline advancement
Open the full interactive Coherus Oncology, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.